The Life Sciences Report: Alain, you have compared the current stage in the development of the stem cell and regenerative medicine industry to the beginning of the monoclonal antibody revolution. Companies formed to leverage stem cell technology have been around now for three decades. When are we going to start to see the approval, marketing and reimbursement of some of these technologies?
A historic look at monoclonals is a very insightful way to understand the stem cell industry, in the sense that it took about 25 years for monoclonal antibodies to emerge as a mainstream product category. As recently as , there were only a handful of companies with double-digit sales derived from monoclonal antibody-based therapies. The transition and penetration of this new technology class started quite slowly. I think we are witnessing something similar with stem cells and regenerative medicine.
Considering only mesenchymal stem cells, I would say that by we should have good clarity regarding deployment in major markets. First of all, we have Prochymal allogeneic human mesenchymal stem cells; [remestemcel-L] , a product developed by Osiris Therapeutics Inc. I think Prochymal, for this particular indication and for this particular patient population, will be one of the first stem cell therapies to hit the market.
It is interesting also to look more closely at what is happening in Japan. That country has a new law that essentially enables companies to more quickly develop and deploy stem cell technologies into the market, as long as safety is demonstrated. This is particularly in response to an aging society, and the observation that conventional pharmaceutical approaches have not satisfactorily addressed a range of indications—for example, stroke as a leading cause of death and disability—that impose high social and financial burdens.
Regenerative medicine products could change this. The Japanese parliament enacted the new law in November , revising the Pharmaceutical Affairs law to define new regenerative medicine products. Companies can now get conditional approval for stem cell products after they show safety, like they would in a Phase 2 trial. On March 2, Chugai Pharmaceutical Co. MultiStem could very well be among the first few products approved in Japan. But then again, the law will be beneficial for all stem cell companies, which is very exciting.
TLSR: We are just starting to see oligonucleotides come to the market as approved therapies. It appears to take a quarter of a century for a new technology to move from lab bench to treating patients. Would you agree? AV: It does appear that way.
And even outside Japan, given the number of trials in Phase 2 and Phase 3 that will be reading out this year or next year, we should see some cell therapy products begin to emerge. TLSR: Unlike cell technologies, the monoclonal antibody industry is relatively straightforward. Monoclonal antibodies act pretty much the same way as small molecules do: They engage or inhibit a protein on a cell membrane to alter signal transduction into and within the cell.
Spanish Property Forums, News & Discussion
Ce lls perform most all metabolic activities, including reproduction. Importantly, they also express multiple genes.
Are we talking about apples and oranges here? AV: I think we can have both perspectives. We can say that stem cells and monoclonals are very much similar in terms of the S-curve of development.
Falsches Spiel: Roman (German Edition)
We had to progress upward on the S-curve from murine to chimeric combining genetic elements from nonhuman and human to humanized, and to fully human antibodies. When we reached the last level, the technology became mature enough to penetrate the market. It was only a question of allowing innovation to take over. If we look at stem cells, we see very similar lower stages of S-curve development. The safety of mesenchymal stem cells is now clear.
But there is a difference. For the first time, we have pharmaceutical-like products—these cells—that are able to be implanted and enrich a target microenvironment. Cell therapies represent a critical development in healthcare because we now have a therapy that is going to understand, for lack of a better term—or rather sense, through a complex network of signal transduction relay molecules—the specifics of the microenvironment it encounters when it is implanted or infused.
These cells will then respond as well as possible based on the area of the body targeted and, of course, based on the specific disease. We thus have the machinery to develop a fresh salvo and create arrays of cytokine growth factors and beneficial effects.
This study, randomized and double-blind with patients, failed to meet its primary endpoint of reducing the incidence and severity of adverse events in ulcerative colitis. Did that have a chilling effect on big pharma companies, which saw Pfizer fail in this trial? Going back to monoclonal antibodies, the first 15 clinical trials were failures. Looking at the details of that Phase 2 trial with MultiStem, Athersys and Pfizer set a very, very high bar for success in terms of trial design.
One reason this was so challenging was that they were essentially attempting to treat patients who were very sick, and who had already failed several types of therapy. TLSR: You said the bar was set very high. Do you think the single-infusion design was a problem? That single infusion of cells was intended to treat or alleviate a disease some patients had been suffering with for a decade, and in some cases for half their lives. AV: That definitely was the case.
Blog - Omega Business Advisors
These patients had chronic moderate to severe disease for an average of ten years, and a single injection may not have been sufficient. Also, maybe the company would need to treat patients earlier in their disease progression. It was a very high bar. Would you summarize your thoughts on Athersys? AV: The stock price has been recovering from the trial failure. As far as MultiStem goes, it has been found to be safe. I do like this company, and its prospects are quite positive. AV: Yes. It has an autologous cell therapy model for hair transplant and Achilles tendinosis.
In addition, the company has developed a very clever way to deliver its autologous cells for both of its indications—a dermal injector device. Its business model offers investors a reasonable cost of goods sold COGS. RepliCel has also established a strategic partnership with Shiseido Company Ltd. This is a partnership with a very good company. Right now, RepliCel is positioned with very good potential.
I do not see any fundamental flaw or problem with this company. TLSR: It has been a rough year for stem cell companies in general. Many companies working in the space have seen double-digit declines in their stock prices. What is going on with Mesoblast?
AV: There has definitely been a group effect with regard to the share prices of all these companies. But the case of Mesoblast is very interesting. The company was at the height of its valuation a couple of years ago, and there was a correction in the stock price, following these systemic trends that you just mentioned.
The key question here is whether there is a major, fundamental issue in the company.